Results 241 to 250 of about 1,007,353 (300)

DNA Nanotechnology Meets Peptide and Protein Self‐Assembly

Chemistry – A European Journal, EarlyView.
Combining DNA nanotechnology with peptide and protein assembly provides complementary platforms for the rational engineering of functional biomaterials. This Perspective discusses the emerging field of self‐assembling DNA‐peptide and DNA‐protein hybrid systems that combine the structural precision and programmability of DNA nanotechnology with the ...
Marcel Hanke, Nanjundan Raghul, Adrian Keller, Veikko Linko, Verónica I. Dodero   +4 more
wiley   +1 more source

Early generational and partisan divides in vaccine acceptance in USA during the COVID-19 pandemic. [PDF]

Health Promot Int
Alonso G, Kiesel S.
europepmc   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

Clinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke, Boitumelo Semete‐Makokotlela, Varnika Singh, Khanyisile Nkuku, Madelein Terblanche, Ezekiel T Mukanga, Nancy Ngum, Kudakwashe Dandajena, McNeil Chimus Mhango, Paulyne Wairimu, John Mwangi, Dominique Lagrave, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

A video-based educational intervention to improve vaccine acceptance for Schistosomiasis japonicum: A pre-post study using the 5C model in rural China. [PDF]

Hum Vaccin Immunother
Yang Q, Wang J, Du C, Lee HY, Wong LP.
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Influence of respiratory disease experiences on COVID-19 vaccine acceptance: a study from Southeastern Louisiana. [PDF]

Front Public Health
Barri S, Al-Dahir S, Heyer K, Taylor A, Khalil A, Belkhouche M, Bonvillain BA, Caldwell K, Surcouf H, Hamed I, Jwayyed M, Craig LS, Sarpong DF, Salmon D.   +13 more
europepmc   +1 more source

How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions

Clinical Pharmacology &Therapeutics, EarlyView.
Healthy volunteers (HVs) are essential for phase I trials, yet their recruitment and screening remain resource‐intensive and ethically complex. High screening failure (SF) rates highlight the need to evaluate and understand all aspects of the enrolment processes. We analyzed SF patterns in a large German HV cohort and explored participants' motivations,
Evelyn Krohmer, Manuela König, Cathrin J. Vogt, Marina Streckebein, Sybille Baumann, Max Blumenstock, Ruwen Böhm, Fabian Müller, Nadja Struß, Viktoria S. Wurmbach, Antje Blank   +10 more
wiley   +1 more source

Health belief model-based peer education to improve human papillomavirus vaccine acceptance: A pilot interventional study among Turkish female midwifery students. [PDF]

Prev Med Rep
Ceylan Ö, Erdoğan EN, Ceylan S, Tahta T, Özdemir H, Yıldız Y, Güvenç G.   +6 more
europepmc   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu, Zhigang Liu, Xiaohu Kuang, Yueming Wang, Xiaoyi Liu, Jiyuan Ding, Xia Zhou, Xin Zhou, Qianyu Liang, Meizhuo Zhang, Hao Zhao, Qingqing Tan, Weihong Zheng, Huaxin Liao, Charlotte Lemech, Wanmei Wang   +15 more
wiley   +1 more source